GlobeNewswire

ProMIS Neurosciences and BC Neuroimmunology announce revenue-sharing joint venture agreement to develop and offer blood-based diagnostic tests for Alzheimer’s disease

Share

Testing of blood-based biomarkers will offer convenient detection and monitoring of disease progression in pre-symptomatic and early Alzheimer’s disease (AD)

TORONTO and CAMBRIDGE, Mass., July 09, 2020 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a company with unique, core technology to predict novel targets (peptide antigens) on the molecular surface of complex, misfolded proteins, and BC Neuroimmunology Lab (BCNI), have entered into a revenue-sharing joint venture (JV) agreement to develop and offer highly accurate and objective tests for detection, diagnosis and monitoring of Alzheimer’s disease (AD).

Significant progress has been made over the past several years to advance a more precise diagnosis of AD. In particular, introduction of the A/T/N (amyloid/tau/neurodegeneration) criteria two years ago offered an unbiased approach for the objective biological diagnosis of AD1. However, the A/T/N diagnostic approach, until recently, required either costly PET and MRI scan assessments or an invasive lumbar puncture to secure cerebrospinal fluid to measure specific biomarkers. 

Impressive scientific advances have been made since the introduction of A/T/N, as exemplified by emerging scientific evidence showing that blood levels of two brain-protein biomarkers2,3, NfL (neurofilament light chain) and P-tau181 (phosphorylated tau181), appear to provide an equally precise A/T/N characterization as imaging or CSF measurements, and can thus offer convenient, cost-effective and objective detection and monitoring of the AD process.

“The progress this year in measuring P-tau181 in the blood marks an inflection point in the fight against Alzheimer’s disease,” stated Eugene Williams, ProMIS Executive Chairman. “We now have blood-based biomarkers that can provide the information necessary to detect Alzheimer’s disease, including pre-symptomatic disease. Measurable Alzheimer’s neuropathology precedes cognitive decline by 15-20 years, and this represents an invaluable window of opportunity for prevention, and prevention begins with detection. ProMIS’ ultimate mission with its partner, BCNI, is to build a portfolio of assays that enables early detection and monitoring of disease progression before symptoms arise.”

The JV/collaboration will first offer existing blood-based assays for NfL and P-tau181. Further assays will be added subsequently, potentially incorporating ProMIS’ proprietary peptide antigens and tests for additional neurodegenerative diseases.

“We know that lifestyle interventions like diet, exercise and mental stimulation can have a significant impact on progression to cognitive decline,” stated Dr. Sharon Cohen, Director of Toronto Memory Program. “What has been missing prior to the recent advent of blood-based biomarkers is a convenient and accurate way to measure the impact of these interventions in pre-symptomatic patients. ProMIS’ exciting work with blood-based biomarkers for the detection and monitoring of AD could potentially contribute to a breakthrough in how we work with our patients to prevent Alzheimer’s disease.”

About BC Neuroimmunology Lab Inc.
BC Neuroimmunology Lab Inc. (BCNI) is a private, full-service clinical neuroimmunology lab located in the University of British Columbia (Vancouver) hospital and has been operational for the past 35 years. BCNI is accredited by both the College of American Pathologists (CAP) and ISO/Diagnostic accreditation program (DAP). BCNI services patients, pharmaceutical companies and contract research organizations from all of North America and is the North American reference center for six high-complexity immunoassays. BCNI has extensive experience and expertise in Surface Plasmon Resonance (SPR), live and fixed cell-based assays, radioimmunoprecipitation assays, ELISA, immunoblot and immunohistochemistry assays.

About ProMIS Neurosciences
ProMIS Neurosciences, Inc. is a development stage biotechnology company whose unique core technology is the ability to rationally predict the site and shape (conformation) of novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of proteins. In neurodegenerative diseases, such as Alzheimer’s, ALS and Parkinson’s disease, the DSEs are misfolded regions on toxic forms of otherwise normal proteins. In the infectious disease setting, these DSEs represent peptide antigens that can be used as an essential component to create accurate and sensitive serological assays to detect the presence of antibodies that arise in response to a specific infection, such as COVID-19. ProMIS proprietary peptide antigens can also be used to create potential therapeutic antibodies, as well as serve as the basis for development of vaccines. ProMIS is headquartered in Toronto, Ontario, with offices in Cambridge, Massachusetts. ProMIS is listed on the Toronto Stock Exchange under the symbol PMN, and on the OTCQB Venture Market under the symbol ARFXF.

Visit us at www.promisneurosciences.com or follow us on Twitter and LinkedIn. To learn more about diagnostic testing for Alzheimer’s disease, listen to Episode 26 of the podcast, Saving Minds, available at iTunes or on ProMIS Neurosciences’ website.

References:
1https://pubmed.ncbi.nlm.nih.gov/29653606/
2https://pubmed.ncbi.nlm.nih.gov/32333900/
3https://pubmed.ncbi.nlm.nih.gov/31009028/

For media inquiries, please contact:
Shanti Skiffington
shanti.skiffington@gmail.com
Tel. 617 921-0808

For Investor Relations please contact:
Alpine Equity Advisors
Nicholas Rigopulos, President
nick@alpineequityadv.com
Tel. 617 901-0785

The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This information release contains certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company's current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Avance Gas Holding Ltd - Notice of Annual General Meeting 202010.8.2020 19:16:03 CESTPress release

Bermuda, 10 August 2020 - Avance Gas Holding Ltd (the "Company") annouces that its 2020 Annual General Meeting will be held on August 31, 2020. A copy of the Notice of Annual General Meeting and associated information including the Company's Consolidated Financial Statements for 2019 can be found on our website at www.avancegas.com and attached to this press release. For further queries, please contact: Peder C. G. Simonsen, interim CEO and CFO Tel: +47 22 00 48 15 Email: p.simonsen@avancegas.com ABOUT AVANCE GAS Avance Gas operates in the global market for transportation of liquefied petroleum gas (LPG). The Company is one of the world's leading owners and operators of very large gas carrier (VLGC), and operates a fleet of fourteen modern ships and two Dual Fuel LPG newbuildings due for delivery in 2021 and 2022. For more information about Avance Gas, please visit: www.avancegas.com. This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Secu

GOGL – Notice of Annual General Meeting 202010.8.2020 19:00:00 CESTPress release

Golden Ocean Group Limited (the “Company”) announces that its 2020 Annual General Meeting will be held on August 31, 2020. A copy of the Notice of Annual General Meeting and associated information including the Company`s Consolidated Financial Statements on Form 20-F for 2019 can be found on our website at www.goldenocean.bm and in the links below. August 10, 2020 The Board of Directors Golden Ocean Group Limited Hamilton, Bermuda This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act Attachments GOGL - 2019 Form 20-FGOGL - Notice of Annual General Meeting 2020

FRO - Notice of Annual General Meeting 202010.8.2020 18:59:56 CESTPress release

Frontline Ltd. (the “Company”) announces that its 2020 Annual General Meeting will be held on August 31, 2020. A copy of the Notice of Annual General Meeting and associated information including the Company’s Annual Report on Form 20-F for 2019 can be found on our website at www.frontline.bm and attached to this press release. August 10, 2020 The Board of Directors Frontline Ltd. Hamilton, Bermuda This information is subject to the disclosure requirements pursuant to section 5 -12 of the Norwegian Securities Trading Act. Attachments FRO - 2019 Annual Report on Form 20-FFRO - Notice of Annual General Meeting 2020

Updated: Verisk Launches EHR Triage Engine to Help Speed Approval of Life Insurance Applications10.8.2020 18:57:23 CESTPress release

Powered by Consumer-Authorized Electronic Health Records, Verisk’s Innovative Solution Can Help Streamline Underwriting Decisions Jersey City, NJ, Aug. 10, 2020 (GLOBE NEWSWIRE) -- Verisk Launches EHR Triage Engine to Help Speed Approval of Life Insurance Applications Powered by Consumer-Authorized Electronic Health Records, Verisk’s Innovative Solution Can Help Streamline Underwriting Decisions JERSEY CITY, N.J., August 10, 2020 — Verisk (Nasdaq:VRSK), a leading data analytics provider, announced today the launch of its new EHR Triage Engine, a tool that uses data from consumer-authorized electronic health records (EHRs) to help life insurers fast-track many applications for coverage—potentially cutting decision time from weeks to minutes. The EHR Triage Engine bypasses manual workflows, leveraging advanced predictive analytics and automation to digitally ingest and analyze EHRs. The tool can evaluate 95,000 impairments in five minutes or less, so life insurers can qualify as much as

EVS Broadcast Equipment reports update of share buyback program10.8.2020 17:45:00 CESTPress release

Publication on August 10, 2020, after market closing Regulated information – reporting share buyback EVS Broadcast Equipment S.A.: Euronext Brussels (EVS.BR), Bloomberg (EVS BB), Reuters (EVSB.BR) EVS reports update of share buyback program EVS Broadcast Equipment reports that the following transactions, conducted within the framework of the share buyback program announced on May 6, 2020, took place between August 3, 2020 and August 7, 2020. DateNumber of shares acquiredAverage price (EUR)Highest price (EUR)Lowest price (EUR)Total (EUR)03/08/20201,98815.147215.2615.02 30,113 04/08/20202,19815.250515.3815.10 33,521 05/08/20202,16915.088615.1815.00 32,727 06/08/20202,14015.009315.1214.80 32,120 07/08/20201,88615.084615.1615.00 28,450 Total10,381 15.1170 15.38 14.80 156,930 As of August 7, 2020, and since the start of the buyback program, EVS has bought 136,971 shares at an average price of EUR 15,6646, representing in total EUR 2,145,601. After aforementioned transactions the total numbe

TOUAX SCA announces that its subsidiary Touax Rail Ltd successfully signed a €81.9 million capital increase to accelerate the development of its freight railcar division in Europe and Asia10.8.2020 17:45:00 CESTPress release

PRESS RELEASE Paris, August 10th, 2020. 5:45pm YOUR OPERATIONAL LEASING SOLUTION FOR SUSTAINABLE TRANSPORTATION TOUAX SCA announces that its subsidiary Touax Rail Ltd successfully signed a €81.9 million capital increase to accelerate the development of its freight railcar division in Europe and Asia Touax SCA announces today that its subsidiary Touax Rail Limited has entered into a final agreement with DIF Capital Partners to increase its capital by €81.9 million to accelerate the development of its long term leasing activities of freight wagons in Europe and Asia. Touax SCA will remain the main shareholder holding 51% of the capital and 49% will be owned by its new partner DIF Capital Partners, through its DIF Core Infrastructure Fund II. The transaction will be immediately accretive for Touax Rail Limited as proceeds will be used on the one hand to buy out minority shareholders in two special purpose companies owning c. 4,000 platforms and in Touax Rail India Limited, and to finance